Centre plans 30% trade-margin cap on cancer drugs
In short
The Centre is planning a 30% cap on trade margins for non-scheduled cancer drugs. The report says retail prices could fall by up to 70%.
This could make cancer medicines cheaper for patients. It is not stated when the cap would start or which drugs are included.
What the reporting says
The Centre is planning a 30% trade-margin cap on non-scheduled cancer drugs, according to the reported summary. Mint said the proposal could cut retail prices by up to 70% and that the government is moving ahead of a broader crackdown on steep mark-ups in cancer medicines. The reporting does not say when the cap would take effect or which drugs would be covered. The immediate consequence could be lower prices for patients if implemented.
Why it matters
The Centre is reported to be moving toward a 30% trade-margin cap on non-scheduled cancer drugs. The summary says this could reduce retail prices by as much as 70%, suggesting a direct impact on medicine pricing and patient costs. The reporting frames it as part of a wider crackdown on large mark-ups, but it does not state the timing, the enforcement mechanism, or the medicines covered.